Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if sorafenib, capecitabine and oxaliplatin (SECOX)
regimen is more effective than sorafenib alone in the treatment of advanced liver cancer.